ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1831

Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database

Eiichi Tanaka1, Eisuke Inoue2, Daisuke Hoshi3, Akiko Kobayashi2, Naoki Sugimoto2, Kumi Shidara2, Eri Sato3, Yasushi Inoue3, Yohei Seto2, Ayako Nakajima4, Shigeki Momohara3, Atsuo Taniguchi2 and Hisashi Yamanaka3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Economics, functional status, quality of life, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable economic burden to society. Several previous studies have investigated the cost-effectiveness of specific BAs; however, they have not adequately considered BA utilization under real-life conditions. In actual clinical conditions, various individual patient-based factors influence BA utilization and timing of selecting, switching, or discontinuing agents. Previous studies on specific BAs considering only a few aspects of the conditions of RA patients in actual clinical practice were frequently based on controlled trials. In this study, we investigated the cost-effectiveness of selecting BAs followed by switching to other BAs or methotrexate (MTX) under actual clinical conditions using RA cohort database, the Institute of Rheumatology, Rheumatoid Arthritis (IORRA).

Methods: A Markov model-based probabilistic simulation from a societal perspective was conducted using a hypothetical population of 10,000 patients. Patients who had failed more than one disease-modifying antirheumatic drug (DMARD) and for whom BAs were selected started one of the four BAs (adalimumab, etanercept, infliximab, and tocilizumab) used in Japan in 2010, switched to other BAs or MTX, or discontinued all drugs comprised the BA group. Patients similar in background to the BA group who started MTX following discontinuation of all drugs comprised the comparator group (MTX group). Almost all model parameters were determined with respect to each group, except those related to effects and costs of the four BAs and MTX, based on clinical data extracted by the matching method from the IORRA. Health states in the model were defined on the basis of physical dysfunction levels stratified according to the Japanese version of the Health Assessment Questionnaire (J-HAQ), which corresponded to cost and utility. Lifetime costs, quality-adjusted life years (QALY), and incremental cost-effectiveness ratio (ICER) were calculated. The threshold ICER was assumed to be 5.0-6.0 million JPY (1 USD = 88 JPY in 2010). A lifetime horizon and a discount rate of 3% per year for both health benefits and costs were assumed. We also conducted a probabilistic sensitivity analysis.

Results: Clinical data from two groups of 454 patients each were used for calculating model parameters (percentages of patients in the BA group started adalimumab, etanercept, infliximab, and tocilizumab were 17.3%, 45.9%, 24.3%, and 12.5%, respectively). Lifetime costs in the BA and MTX groups were 34.8 and 24.1 million JPY and QALYs were 11.4 and 9.3, respectively. The average period with acceptable disability defined by J-HAQ <1.1 was longer in the BA group (15.8 years) than that in the MTX group (10.4 years). The ICER was 5.04 million JPY, with 75.8-89.1% probability of falling below 5.0-6.0 million JPY, respectively, according to probabilistic sensitivity analysis.

Conclusion: This study demonstrated that selecting BAs is cost-effective for RA patients who had failed more than one DMARD according to the analysis of data obtained from an observational cohort representing daily clinical practice in Japan.


Disclosure:

E. Tanaka,
None;

E. Inoue,
None;

D. Hoshi,
None;

A. Kobayashi,
None;

N. Sugimoto,
None;

K. Shidara,
None;

E. Sato,
None;

Y. Inoue,
None;

Y. Seto,
None;

A. Nakajima,
None;

S. Momohara,
None;

A. Taniguchi,
None;

H. Yamanaka,

Abbott Japan, Bristol-Myers Japan, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co. Ltd., and Pfizer Japan Inc.,

2,

Abbott Japan, Bristol-Myers Japan, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co. Ltd., and Pfizer Japan Inc.,

5,

Abbott Japan, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co. Ltd., and Pfizer Japan Inc.,

8,

IORRA study is supported by 40 pharmaceutical companies.,

.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-cost-effectiveness-of-rheumatoid-arthritis-treatment-with-biologic-agents-using-the-iorra-cohort-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology